Merck KGaA is confident that it can continue to grow in the multiple sclerosis space, with Mavenclad and evobrutinib hopefully filling the revenue gap created by the continued decline of Rebif sales.
The German group has unveiled a reasonable set of financials for the first quarter with healthcare sales rising 3.2% to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?